文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

LRIG2 通过调节巨噬细胞浸润和极化来促进胶质母细胞瘤的进展，从而抑制固有抗肿瘤免疫。

LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization.

机构信息

Department of Neurosurgery, Huazhong University of Science and Technology, Tongji Hospital, Tongji Medical College, Wuhan, Hubei, China.

Department of Neurosurgery, The First People's Hospital of Yichang, China Three Gorges University People's Hospital, Yichang, Hubei, China.

出版信息

J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2021-004452.

DOI:10.1136/jitc-2021-004452
PMID:36096529
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9472135/
Abstract

BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tumor-associated microglia/macrophages (TAMs). RESULTS: High level of LRIG2/soluble LRIG2 (sLRIG2) expression activates immune-related signaling pathways, which are associated with poor prognosis in GBM patients. LRIG2/sLRIGs promotes CD47 expression and facilitates TAM recruitment. Blockade of CD47-SIRPα interactions and inhibition of sLRIG2 secretion synergistically suppress GBM progression in an orthotropic murine GBM model. CONCLUSIONS: GBM cells with high level LRIG2 escape the phagocytosis by TAM via the CD47-SIRPα axis, highlighting a necessity for an early stage of clinical trial targeting LRIG2 and CD47-SIRPα as a novel treatment for patients with GBM.

摘要

背景：胶质母细胞瘤（GBM）是最常见的恶性脑肿瘤，临床预后较差。免疫疗法最近成为治疗颅外恶性肿瘤的一种有吸引力和有前途的治疗方法，然而，由于肿瘤相关的小胶质细胞/巨噬细胞（TAMs）的主要积累，大多数 GBM 免疫疗法的临床试验都失败了。

结果：LRIG2/可溶性 LRIG2（sLRIG2）的高表达激活了与 GBM 患者预后不良相关的免疫相关信号通路。LRIG2/sLRIG2 促进 CD47 的表达并促进 TAM 的募集。阻断 CD47-SIRPα 相互作用和抑制 sLRIG2 分泌协同抑制原位小鼠 GBM 模型中的 GBM 进展。

结论：高水平 LRIG2 的 GBM 细胞通过 CD47-SIRPα 轴逃避 TAM 的吞噬作用，凸显了针对 LRIG2 和 CD47-SIRPα 的临床试验早期的必要性，这为 GBM 患者提供了一种新的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/0427904d15a9/jitc-2021-004452f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/368894ab346e/jitc-2021-004452f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/7f83d205ec42/jitc-2021-004452f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/e9dbda4aad38/jitc-2021-004452f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/47c03ab324ef/jitc-2021-004452f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/0427904d15a9/jitc-2021-004452f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/368894ab346e/jitc-2021-004452f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/7f83d205ec42/jitc-2021-004452f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/e9dbda4aad38/jitc-2021-004452f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/47c03ab324ef/jitc-2021-004452f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/936c/9472135/0427904d15a9/jitc-2021-004452f05.jpg

相似文献

[1]
LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization.

J Immunother Cancer. 2022-9

[2]
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.

Front Immunol. 2020

[3]
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma.

Proc Natl Acad Sci U S A. 2019-1-2

[4]
Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.

Cancer Res. 2019-3-21

[5]
LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.

Int J Oncol. 2018-7-16

[6]
Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.

Carcinogenesis. 2018-5-3

[7]
Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis.

Cell Commun Signal. 2024-1-5

[8]
Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.

Oncotarget. 2017-2-14

[9]
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.

J Hematol Oncol. 2020-11-30

[10]
Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.

J Control Release. 2023-8

引用本文的文献

[1]
Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.

Curr Issues Mol Biol. 2024-7-23

[2]
Deciphering the role of CD47 in cancer immunotherapy.

J Adv Res. 2024-9

[3]
Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy.

Front Immunol. 2023

[4]
The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches.

Int J Mol Sci. 2023-1-19

[5]
Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth.

Cell Death Dis. 2023-1-13

[6]
Microglia and Brain Macrophages as Drivers of Glioma Progression.

Int J Mol Sci. 2022-12-9

本文引用的文献

[1]
Single-cell image analysis reveals a protective role for microglia in glioblastoma.

Neurooncol Adv. 2021-5-4

[2]
EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion.

J Exp Clin Cancer Res. 2021-5-8

[3]
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.

Nat Commun. 2021-1-19

[4]
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.

Front Immunol. 2020

[5]
The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.

Neurooncol Adv. 2019-9-6

[6]
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity.

Nat Commun. 2020-6-3

[7]
Ectosomal PKM2 Promotes HCC by Inducing Macrophage Differentiation and Remodeling the Tumor Microenvironment.

Mol Cell. 2020-5-28

[8]
Human chimeric antigen receptor macrophages for cancer immunotherapy.

Nat Biotechnol. 2020-3-23

[9]
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.

Nat Commun. 2020-3-20

[10]
Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.

Cancer Gene Ther. 2020-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索